Tissue Repair Ltd

ASX:TRP Stock Report

Market Cap: AU$16.0m

Tissue Repair Valuation

Is TRP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TRP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TRP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRP?

Key metric: As TRP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TRP. This is calculated by dividing TRP's market cap by their current revenue.
What is TRP's PS Ratio?
PS Ratio8.8x
SalesAU$1.79m
Market CapAU$16.02m

Price to Sales Ratio vs Peers

How does TRP's PS Ratio compare to its peers?

The above table shows the PS ratio for TRP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.9x
IMC Immuron
3.5x59.7%AU$17.2m
CHM Chimeric Therapeutics
1.1xn/aAU$9.1m
BDX BCAL Diagnostics
12.7x77.6%AU$37.7m
NSB NeuroScientific Biopharmaceuticals
2.4xn/aAU$5.4m
TRP Tissue Repair
8.8xn/aAU$16.0m

Price-To-Sales vs Peers: TRP is expensive based on its Price-To-Sales Ratio (8.8x) compared to the peer average (4.9x).

Price to Sales Ratio vs Industry

How does TRP's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARX Aroa Biosurgery
3.6x20.1%US$142.40m
IMC Immuron
3.5x59.7%US$11.17m
ATH Alterity Therapeutics
4x25.0%US$10.38m
BNO Bionomics
2.4x-5.3%US$9.52m
TRP 8.8xIndustry Avg. 10.0xNo. of Companies8PS01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TRP is good value based on its Price-To-Sales Ratio (8.8x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is TRP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TRP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

7D

0%

1Y

6.1%

AVITA Medical

US$339.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.92

7D

2.3%

1Y

25.0%

AVITA Medical

US$342.3m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.97

7D

0.3%

1Y

19.6%